Evidence map›Paper›PMID 26932182›Full record

ArticleScientific reports2016

Cyclophilin A (CypA) Plays Dual Roles in Regulation of Bone Anabolism and Resorption.

Mian Guo, Aaron W James, Jin Hee Kwak, Jia Shen, Kazunari K Yokoyama, Kang Ting, Chia B Soo, Robert H Chiu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Cyclophilin A Promotes Osteoblast Differentiation by Regulating Runx2.International journal of molecular sciences · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Mian GuoDental and Craniofacial Research Institute and Division of Oral Biology, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Aaron W JamesDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Jin Hee KwakDental and Craniofacial Research Institute and Section of Orthodontics, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Jia ShenDental and Craniofacial Research Institute and Section of Orthodontics, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Kazunari K YokoyamaGraduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
Kang TingDental and Craniofacial Research Institute and Section of Orthodontics, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Chia B SooDepartment of Orthopedic Surgery, School of Medicine, University of California, Los Angeles, CA 90095, USA.
Robert H ChiuDental and Craniofacial Research Institute and Division of Oral Biology, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USKaohsiung Medical University · TW

Funding

NELL-1's functional role in cartilage regenerationR01AR068835 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EASLEY, JEREMIAH, SOO, CHIA · 2015 to 2019
$2.2M
NELL-1 Systemic Therapy for OsteoporosisR01AR066782 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EASLEY, JEREMIAH, TING, KANG · 2014 to 2018
$2.0M
Wnt and PPARy Signaling in Nell-1 and BMP2 Mediated Bone RegenerationR01AR061399 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SOO, CHIA · 2012 to 2016
$1.7M
NELL-1 isoforms for the systemic treatment of osteoporosisK08AR068316 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMES, AARON W · 2015 to 2019
$534k
NIAMS NIH HHS AR066782NIAMS NIH HHS AR068835NIAMS NIH HHS K08 AR068316NIAMS NIH HHS R01 AR061399NIAMS NIH HHS R01 AR066782NIAMS NIH HHS R01 AR068835
6 · The paper itself

Abstract

CypA (Cyclophilin A) is a peptidyl-prolyl isomerase previously shown to be required for chondrogenic differentiation and endochondral ossification. However, the effects of CypA on osteoclast activity and bone maintenance are entirely unknown. Here, we show that Ppia(-/-) mice demonstrate low bone mineral density, reduced osteoblast numbers, and increased osteoclast numbers. When isolated from the calvaria, Ppia(-/-) osteoblasts demonstrate decreased osteogenic differentiation, whereas Ppia(-/-) osteoclasts derived from the long bones showed increased osteoclastic activity. Overexpression and gene silencing of CypA verified osteogenic and anti-osteoclastic effects. In osteoblasts, CypA is necessary for BMP-2 (Bone Morphogenetic Protein-2)-induced Smad phosphorylation. In osteoclasts, loss of CypA activates BtK (Bruton's tyrosine kinase) and subsequently integrates with TRAF6 (TNF receptor-associated factor 6) and/or c-fos signaling to induce NFATc1 (nuclear factors of activated T cells, cytoplasmic 1). Collectively, CypA dually exerts pro-osteogenic and anti-osteoclastic effects. Thus, modulation of CypA may be useful in future efforts targeting osteoporosis.

Indexed as

AnimalsBone and BonesBone ResorptionCyclophilin AGene Knockdown TechniquesImmunohistochemistryMiceMice, Inbred C57BLMice, KnockoutOsteoblastsOsteoclastsRAW 264.7 CellsSignal TransductionX-Ray MicrotomographyCyclophilin A

Identifiers

PMID26932182
PMCPMC4774113
OpenAlexW2330268131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.